EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access · CC BY-NC 4.0

Live two‐way video versus face‐to‐face treatment for depression, anxiety, and obsessive‐compulsive disorder: A 24‐week randomized controlled trial

Taishiro Kishimoto iD, Shotaro Kinoshita, Momoko Kitazawa, Akitoyo Hishimoto iD, Takeshi Asami, Akira Suda, Shogyoku Bun, Toshiaki Kikuchi, Mitsuhiro Sado iD, Akihiro Takamiya, Masaru Mimura iD, Yasunori Sato und 24 weitere

Psychiatry and Clinical Neurosciences · 2024

DOI: 10.1111/pcn.13618 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Psychiatry and Clinical Neurosciences, 2024. Verfasst von Taishiro Kishimoto und 35 weiteren Autor:innen. Beteiligte Einrichtung: Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Depression, Obsessive-Compulsive Disorder. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Live two‐way video, easily accessible from home via smartphones and other devices, is becoming a new way of providing psychiatric treatment. However, lack of evidence for real‐world clinical setting effectiveness hampers its approval by medical insurance in some countries. Here, we conducted the first large‐scale pragmatic, randomized controlled trial to determine the effectiveness of long‐term treatment for multiple psychiatric disorders via two‐way video using smartphones and other devices, which are currently the primary means of telecommunication.

Methods

This randomized controlled trial compared two‐way video versus face‐to‐face treatment for depressive disorder, anxiety disorder, and obsessive‐compulsive disorder in the subacute/maintenance phase during a 24‐week period. Adult patients with the above‐mentioned disorders were allocated to either a two‐way video group (≥50% video sessions) or a face‐to‐face group (100% in‐person sessions) and received standard treatment covered by public medical insurance. The primary outcome was the 36‐Item Short‐Form Health Survey Mental Component Summary (SF‐36 MCS) score. Secondary outcomes included all‐cause discontinuation, working alliance, adverse events, and the severity rating scales for each disorder.

Results

A total of 199 patients participated in this study. After 24 weeks of treatment, two‐way video treatment was found to be noninferior to face‐to‐face treatment regarding SF‐36 MCS score (48.50 vs 46.68, respectively; p < 0.001). There were no significant differences between the groups regarding most secondary end points, including all‐cause discontinuation, treatment efficacy, and satisfaction.

Conclusion

Two‐way video treatment using smartphones and other devices, was noninferior to face‐to‐face treatment in real‐world clinical settings. Modern telemedicine, easily accessible from home, can be used as a form of health care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DepressionObsessive-Compulsive DisorderAdultHumansAnxiety DisordersAnxietyPsychotherapyTreatment Outcome

Stichwörter der Autor:innen

anxiety disorderdepressionlong‐term treatmentobsessive‐compulsive disordertwo‐way video

Autor:innen und Institutionen

  • Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Tokyo, Japan.
  • Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Tokyo, Japan.
  • Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
  • Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan.
  • Psychiatric Center, Yokohama City University Medical Center, Yokohama, Japan.

ORCID-Profile: Taishiro Kishimoto, Akitoyo Hishimoto, Mitsuhiro Sado, Masaru Mimura, Kengo Nagashima, Takashi Nakamae, Yoshinari Abe, Hiroaki Tomita, Michitaka Funayama

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Kishimoto, T., Kinoshita, S., Kitazawa, M., Hishimoto, A., Asami, T., Suda, A., Bun, S., Kikuchi, T., Sado, M., Takamiya, A., Mimura, M., Sato, Y., Takemura, R., Nagashima, K., Nakamae, T., Abe, Y., Kanazawa, T., Kawabata, Y., Tomita, H., …, & J‐PROTECT collaborators (2024). Live two‐way video versus face‐to‐face treatment for depression, anxiety, and obsessive‐compulsive disorder: A 24‐week randomized controlled trial. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13618

Vancouver

Kishimoto T, Kinoshita S, Kitazawa M, Hishimoto A, Asami T, Suda A, et al. Live two‐way video versus face‐to‐face treatment for depression, anxiety, and obsessive‐compulsive disorder: A 24‐week randomized controlled trial. Psychiatry and Clinical Neurosciences. 2024. doi:10.1111/pcn.13618

BibTeX
@article{Kishimoto2024,
  author = {Kishimoto, Taishiro and Kinoshita, Shotaro and Kitazawa, Momoko and Hishimoto, Akitoyo and Asami, Takeshi and Suda, Akira and Bun, Shogyoku and Kikuchi, Toshiaki and Sado, Mitsuhiro and Takamiya, Akihiro and Mimura, Masaru and Sato, Yasunori and Takemura, Ryo and Nagashima, Kengo and Nakamae, Takashi and Abe, Yoshinari and Kanazawa, Tetsufumi and Kawabata, Yasuo and Tomita, Hiroaki and Abe, Koichi and Hongo, Seiji and Kimura, Hiroshi and Sato, Aiko and Kida, Hisashi and Sakuma, Kei and Funayama, Michitaka and Sugiyama, Naoya and Hino, Kousuke and Amagai, Toru and Takamiya, Maki and Kodama, Hideyuki and Goto, Kenichi and Fujiwara, Shuichiro and Kaiya, Hisanobu and Nagao, Kiichiro and J‐PROTECT collaborators, J‐PROTECT collaborators},
  title = {Live two‐way video versus face‐to‐face treatment for depression, anxiety, and obsessive‐compulsive disorder: A 24‐week randomized controlled trial},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2024},
  doi = {10.1111/pcn.13618}
}
Kostenlos starten →